Pfizer's sky-high dividend yield is tempting, but is it sustainable?High-yield dividend stocks offer two key benefits. They provide regular cash flow through dividend payments and, when dividends are consistently reinvested, have often outperformed the S&P 500 over extended periods.High yields, however, warrant scrutiny. They often result from falling share prices or overly generous payout policies. The payout ratio, which measures the proportion of earnings distributed as dividends, is a critical metric. R ...

Pfizer's experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial, the drugmaker said Saturday. Patients with the condition, called cancer cachexia, who took Pfizer's treatment saw improvements in body weight, muscle mass, quality of life and physical function, according to the drugmaker. The results could pave the way for the drug, a monoclonal antibody called ponsegromab, to become the first treatme ...

Blister packets each containing a dose of PAXLOVID prescription medicine for a patient's Covid-19 ... [+] viral infection are arranged for a photo illustration on September 4, 2024 in Los Angeles, California. (Photo by Patrick T. Fallon / AFP) (Photo by PATRICK T. FALLON/AFP via Getty Images)AFP via Getty ImagesGiven its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward, versu ...

Pfizer (PFE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a chan ...

They're down but not out, at least not yet.The stock market has been on fire this year, but much of that performance can be attributed to a handful of tech giants that have a disproportionate weight of the S&P 500 and are benefiting from the artificial intelligence (AI) boom. Many other stocks have been doing well, but it's not that hard to find those moving in the opposite direction.Pharmaceutical giant Pfizer (PFE 1.12%) and social media platform Snap (SNAP 1.29%) belong to this group: Both have significa ...

Pfizer (PFE) closed at $29.74 in the latest trading session, marking a +1.11% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.45%. Elsewhere, the Dow saw a downswing of 0.23%, while the tech-heavy Nasdaq appreciated by 0.84%.The drugmaker's stock has climbed by 3.37% in the past month, exceeding the Medical sector's gain of 3.16% and the S&P 500's gain of 2.54%.Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upcomin ...

no_limit_pictures Intro & Thesis I reinitiated my coverage of Pfizer Inc. (NYSE:PFE) stock at the end of December 2023 with a "Buy" rating, when the stock was trading at $27.86 apiece. Since then, I have published 3 more articles, which, ultimately, have proven effective in terms of relative and absolute performance: PFE's total return outpaced the S&P 500 index (SP500) (SPX) quite meaningfully. The index has remained stagnant, hovering around 0% over the past 3 months, while PFE gave a total return of over ...

Investment Thesis - Pfizer's stock delivered a total return of 6.5% since February, underperforming the broader market's 7.3% return [1] - The company secured FDA approval for its KP.2-adapted COVID-19 vaccine, positioning it well for the 2024-2025 season [1] - Core products like Eliquis, Vyndaqel, and newer oncology therapies, along with Seagen acquisitions, are driving growth [1] - Pfizer is expanding into obesity treatments and oncology through key R&D investments, diversifying its pipeline [1] - Technical indicators suggest potential stock strength, with RSI trending upward and early signs of accumulation in VPT [1][3] Technical Analysis - Pfizer's current stock price of $28.5 aligns with the pessimistic 2024 price target based on the 0.382 Fibonacci level [2] - The average price target of $31 (1.0 Fibonacci level) suggests modest upside, while the optimistic target of $33 (1.618 Fibonacci level) indicates potential for stronger gains [2][3] - RSI at 51.84 indicates neutral market sentiment, but the upward trend suggests potential stock strength [3] - VPT shows signs of upward reversal, indicating possible accumulation [3] - Historical seasonality data suggests stronger performance in October (62% chance of positive returns) and November (70% chance) [4] COVID-19 Vaccine Market - Pfizer's KP.2-adapted COVID-19 vaccine, developed with BioNTech, is FDA-approved for the 2024-2025 season [5][6] - The COVID-19 vaccine market is projected to reach $25.6 billion by 2024, with the US contributing $4.39 billion [7] - Pfizer expects the KP.2 vaccine to capture substantial market share, supported by FDA recommendations [6] - The market faces a compound annual growth rate of -17.64% from 2024 to 2029 [7] Financial Performance - Pfizer's Q2 2024 revenue reached $13.3 billion, marking 3% annual operational growth [8] - Excluding COVID-related products, operational revenue growth was 14% [8] - Adjusted gross margin improved to 79% from 76% last year, driven by a favorable sales mix of non-COVID products [8] - Core products like Eliquis, Vyndaqel, and Xtandi drove revenue growth, with Eliquis capturing a growing share of the oral anticoagulant market [9] - Nurtec experienced a 44% annual increase in global operational revenue [9] Oncology and R&D - Pfizer's oncology segment, bolstered by the Seagen acquisition, is seeing growth with products like Padcev, Xtandi, Lorbrena, and Braftovi-Mektovi [9] - Full FDA approval for Tivdak and positive CHMP opinions for Braftovi-Mektovi and Padcev in Europe are critical milestones [9] - R&D expenses increased by 2% operationally in Q2 2024, with a focus on obesity treatments like danuglipron, an oral GLP-1 receptor agonist [9] - Positive results from the Phase 3 CROWN study of Lorbrena in ALK-positive metastatic non-small cell lung cancer showed 60% of patients living beyond five years without disease progression [9] Manufacturing and Cost Management - Pfizer's Manufacturing Optimization Program aims to deliver $1.5 billion in savings by 2027, with savings expected to start in 2025 [9] - The program focuses on improving operational efficiency and realigning the cost base to hit pre-pandemic operating margins [9] - Fiscal year-end revisions show 20 EPS upward revisions and 16 revenue upward revisions, with only 3 revenue downward revisions [10] Revenue Risks and Market Competition - Pfizer remains partially dependent on COVID-19 products, with Q2 2024 COVID-related sales forecast at $8.5 billion [11] - The COVID-19 vaccine market is increasingly competitive, with companies like Moderna and new entrants developing alternatives [11] - Evolving virus strains and competitor advancements create challenges for sustaining market share [12] - Revenue estimates for December 2024 are $60.99 billion, with annual growth of 4.27%, and a P/S ratio of 2.70 [12] - By December 2025, revenue may reach $63.11 billion, with a forward P/S ratio of 2.60 [12] Long-Term Growth Narrative - Despite near-term challenges from fluctuating COVID-19 demand and market competition, Pfizer's strong core portfolio and strategic pipeline investments present a solid growth narrative in the long term [14]

It's not hard to see how these well-seasoned businesses could deliver heaps of passive income to patient investors.There are a million and one ways to make a buck on Wall Street, but some methods are more reliable than others. If you're an investor looking for a way to beef up your passive income stream or you simply want big gains, buying dividend-paying stocks and holding them is a relatively easy way to make it happen.Dividend-payers have to manage their cash more carefully than non-dividend-payers, whic ...

JHVEPhoto Investing in stocks is not for the faint-hearted. Investing in biotech stocks is certainly not for everyone. There are a lot of external factors at play determining the profitability of a biotech company, and even the biggest players in this industry are not immune to regulatory and competitive threats. As a growth investor, though, it is imperative for me to be comfortable with the risks associated with biotech companies, which is why I have invested in a few interesting companies in this spa ...